/

Mechanism Of Action (MOA) Animation

Oncology MOD and MOA Animation

Created for Exelixis, Inc

The project

We created this combination MOD-MOA animation to drive awareness and interest in a new investigational compound, the multi-receptor tyrosine kinase (RTK) inhibitor zanzalintinib. Our team took a deep dive into RTK signaling in cancer to emphasize the rigorous scientific evidence backing the zanzalintinib clinical program—a primary goal for our client. The animation won the AMI Award of Excellence in 2022.

Created for
Exelixis, Inc

More

Mechanism Of Action (MOA) Animation

Title screen from XL309 MOA animation. SL is an emerging strategy for targeting cancer cells. Our client’s lead SL candidate, XL309, inhibits USP1, a deubiquitinase essential for single-strand DNA break repair. Due to compensatory DNA repair mechanisms, XL309 has no effect on healthy cells. However, XL309 is lethal in cancers with homologous recombination (HR)-deficiency that have genetic alterations impairing double-strand DNA break repair. To explain this complex story to multiple audiences, we created a clear, concise MOA animation. Flowchart-like 3D motion graphics make it easy to follow the complex interplay of DNA damage repair mechanisms, while molecular scenes illustrate how the different proteins interact to orchestrate DNA repair.

Synthetic lethality (SL) Mechanism of Action (MOA) Animation

Exelixis, Inc.

Still image of ZORYVE (roflumilast) cream on a skin cube from a plaque psoriasis drug MOA animation.

Plaque Psoriasis Drug MOA Animation

Arcutis Biotherapeutics

axs-studio-medical-animation-cancer-moa-xb002-01

Medical Animation: Cancer ADC MOA

Exelixis, Inc.

Still image of the CMB complex from a cancer pathway MOD/MOA animation.

Medical Animation: Cancer Small Molecule MOA

Exelixis, Inc.

Still image from the Certepetide MOA animation showing a solid tumor growing.

Scientific Animation: Certepetide MOA

Lisata Therapeutics

Title slide from zanzalintinib (XL092) mechanism of action (MOA) animation. XL092 is a small-molecule inhibitor of multiple receptor tyrosine kinases (RTKs) that are involved in cancer growth and immune regulation. Animation is divided into chapters. A web-based interactive version of the video was developed for use at congresses. Animation launched at AACR 2022.

Oncology MOD and MOA Animation

Exelixis, Inc

axs-studio-medical-animation-melanoma-BRAF-MOA-01b

Medical Animation: BRAF Inhibitor for Melanoma

Biopharmaceutical client

axs-studio-medical-animation-hodgkin-lymphoma-immunotherapy-MOA-Reed-Sternberg-cell

Hodgkin Lymphoma Immunotherapy Animation

Biopharmaceutical client

axs-studio-medical-animation-antibody-drug-conjugate-endocytosis

Medical Animation: Immuno-Oncology ADC MOA

Biopharmaceutical client

axs-studio-medical-animation-oncology-immunotherapy-trojan

Medical Animation: Cancer Immunotherapy MOA

Biopharmaceutical client

axs-studio-medical-animation-osteoporosis-drug-MOA-01

Osteoporosis Animation: Sclerostin Inhibitor MOA

Biopharmaceutical client

axs-studio-medical-animation-ldl-recector-mab

Medical Animation: PCSK9 LDL Cholesterol Regulation MOA

Biopharmaceutical Client